Stopping GLP-1 Drugs Raises Risk of Stroke and Heart Attack by 22 Percent Within Two Years, Study Finds
A large-scale study published this week found that patients who stopped taking GLP-1 medications such as Ozempic and Wegovy faced a 22 percent higher risk of stroke, heart attack, and death within two years compared to those who stayed on the drugs. Researchers said the findings highlight the importance of long-term adherence for patients with cardiovascular risk factors.
Patients who stop taking GLP-1 medications face a 22 percent higher risk of stroke, heart attack, and death within two years compared to those who continue treatment, according to a large-scale study reported by Science Daily on September 22, 2026.
GLP-1 receptor agonists, which include drugs sold under brand names such as Ozempic, Wegovy, Mounjaro, and Zepbound, have become widely prescribed for weight loss and type 2 diabetes management. The medications have also been shown to reduce cardiovascular risk in patients with obesity or metabolic disease.
The new study tracked patients who discontinued GLP-1 therapy and compared their outcomes to those who remained on the drugs. Researchers found that the cardiovascular benefits of the medications diminish rapidly after stopping, with the elevated risk becoming apparent within the first two years of discontinuation.
The findings raise questions about how long patients need to stay on GLP-1 drugs to maintain their cardiovascular benefits. Many patients stop taking the medications due to cost, side effects, or the belief that they have achieved their weight-loss goals.
Researchers said the results do not mean that everyone who stops GLP-1 therapy will have a heart attack or stroke, but that the risk is meaningfully higher for those with existing cardiovascular risk factors. They recommended that patients discuss the long-term implications of stopping with their doctors before making a decision.
The study adds to a growing body of research on the broader health effects of GLP-1 medications beyond weight loss. Earlier studies have suggested the drugs may also reduce the risk of kidney disease, sleep apnea, and certain liver conditions.
